Skip to main content

Posts

Showing posts from April 15, 2025

#China reported three additional cases of #human #infection with avian #influenza virus #H9N2 (HK CHP)

{Excerpt} Avian influenza A(H9N2) :  -- Guangxi Zhuang Autonomous Region :  - A five-year-old boy with onset on March 3, 2025.  -- Guizhou Province :  - A 35-year-old woman with onset on March 10, 2025.  -- Henan Province - A seven-year-old girl with onset on February 11, 2025.  (...) Source: Centre for Health Protection, Hong Kong PRC SAR,  https://www.chp.gov.hk/files/pdf/2025_avian_influenza_report_vol21_wk15.pdf ____

#Prevention and #control of avian #influenza virus: Recent advances in diagnostic technologies and #surveillance strategies

{Summary} The natural host for avian influenza virus (AIV) is waterfowl . However, certain subtypes have breached species barriers , causing epizootics in many avian and mammalian species with occasional zoonotic infections in humans . The ongoing spread of highly pathogenic avian influenza (HPAI) A( H5N1 ) poses a significant and growing public health threat . Here, we discuss recent advances in viral detection and characterization technologies and their integration into the diagnostics and surveillance of AIV within a “One Health” framework. Source: Nature Communications,  https://www.nature.com/articles/s41467-025-58882-4 ____

Coadministration of #ribavirin and #arenaviral entry #inhibitor LHF-535 enhances antiviral benefit against authentic #Lassa virus

{Excerpt} Highlights •  A new strain of Lassa virus (LASV) was successfully isolated and characterized. •  The combination of ribavirin and LHF-535 has been demonstrated to exhibit synergistic effects in inhibiting LASV. •  The findings provide new directions for the development of antiviral drugs and vaccines for Lassa fever. Dear Editor, Lassa virus (LASV) is the causative agent of the acute viral hemorrhagic Lassa fever (LF), which is classified into Mammarenavirus within the Arenaviridae family , with a single-stranded, negative-sense, bi-segmented RNA genome. Due to its high pathogenicity and lethality , LASV is considered as a priority threat to public health , with an estimated cases of 300,000 infections and 5,000 deaths annually . LASV was first isolated and described as a clinical entity in 1969 in Lassa, Nigeria (Garry, 2023). LASV isolates of different geographic and host origins are highly diverse in genomic sequences and phylogenetically classified into up t...